Inoue M, Matsumoto S, Saito H, Tsujitani S, Ikeguchi M.. Intraperitoneal administration of a small interfering RNA targeting nuclear factor-kappa B with paclitaxel successfully prolongs the survival of xenograft model mice with peritoneal metastasis of gastric cancer. Int J Cancer 123: 2696-2701

Division of Surgical Oncology, Department of Surgery, Faculty of Medicine, Yonago, Japan.
International Journal of Cancer (Impact Factor: 5.09). 12/2008; 123(11):2696-701. DOI: 10.1002/ijc.23867
Source: PubMed


Activation of nuclear factor-kappa B (NF-kappaB) has been detected in various malignant tumors, including gastric carcinoma, and is associated with tumor growth, metastasis, resistance to chemotherapeutic agents and poor prognosis. Therefore, NF-kappaB is a potential target for antitumor therapy. In this study, we used a small interfering RNA (siRNA) to knockdown NF-kappaB p65 expression and determined whether intraperitoneal administration of NF-kappaB p65 siRNA and paclitaxel was effective for treating peritoneal metastasis of gastric cancer. Western blot analysis revealed that NF-kappaB p65 expression was diminished by NF-kappaB p65 siRNA. Apoptotic cells were increased after transfection of NF-kappaB p65 siRNA compared with control siRNA in the treatment with paclitaxel. In a murine xenograft model, abundant fluorescence was observed on the surface of intraperitoneal nodules of gastric cancer after siRNA administration. Moreover, intraperitoneal administration of NF-kappaB p65 siRNA reduced NF-kappaB expression in intraperitoneal nodules of gastric cancer. Finally, mice treated by intraperitoneal administration of NF-kappaB p65 siRNA and paclitaxel survived for a significantly longer time than mice treated by intraperitoneal administration of paclitaxel alone (p = 0.0002). Taken together, the present results demonstrate that intraperitoneal administration of NF-kappaB p65 siRNA and paclitaxel inhibited cancer growth in mice with peritoneal metastasis of gastric cancer. Therefore, intraperitoneal administration of NF-kappaB p65 siRNA and paclitaxel may provide a breakthrough in the treatment of peritoneal metastasis of gastric cancer.

Download full-text


Available from: Shunichi Tsujitani, Nov 20, 2014
  • Source
    • "Only a few papers describe non-viral siRNA based strategies to inhibit NF-κB activation in animal models of diseases. Lipid based siRNA-mediated knock-down of p65 via intraperitoneal administration in combination with paclitaxel prolonged survival in a mouse model of peritoneal metastasis of gastric cancer [163], suggesting that this approach may also be beneficial in humans via sensitization of tumor cells to chemotherapy. Recently, it was demonstrated that siRNA-mediated reduction of IKKβ prevented TNFα-induced insulin resistance in human skeletal muscle ex vivo [164], possibly reducing insulin resistance. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Nuclear factor (NF)-kappaB is regarded as one of the most important transcription factors and plays an essential role in the transcriptional activation of pro-inflammatory cytokines, cell proliferation and survival. NF-kappaB can be activated via two distinct NF-kappaB signal transduction pathways, the so-called canonical and non-canonical pathways, and has been demonstrated to play a key role in a wide range of inflammatory diseases and various types of cancer. Much effort has been put in strategies to inhibit NF-kappaB activation, for example by the development of pharmacological compounds that selectively inhibit NF-kappaB activity and therefore would be beneficial for immunotherapy of transplantation, autoimmune and allergic diseases, as well as an adjuvant approach in patients treated with chemotherapy for cancer. Gene therapy targeting NF-kappaB is a promising new strategy with the potential of long-term effects and has been explored in a wide variety of diseases, ranging from cancer to transplantation medicine and autoimmune diseases. In this review we discuss recent progress made in the development of NF-kappaB targeted gene therapy and the evolution towards clinical application.
    Current Gene Therapy 07/2009; 9(3):160-70. DOI:10.2174/156652309788488569 · 2.54 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Activated nuclear factor-kappaB (NF-kappaB) is associated reportedly with the pathogenesis of numerous malignancies. This study investigated whether a common insertion (ins)/deletion (del) polymorphism (-94 ins/del ATTG) in the NFKB1 promoter is associated with susceptibility to gastric cancer and its tumor behavior. Blood samples from 182 gastric cancer patients and 116 controls were examined by polymerase chain reaction-based genotyping. Allelotype and genotype (polymorphism) of NFKB1 promoter in gastric cancer patients were analyzed with controls and patients' clinicopathologic factors to evaluate their association using a multivariate analytical model. The mean ages of patients and controls were 65.7 +/- 12.8, and 64.9 +/- 8.8 years old, respectively. Sex ratios (male to female) were 2.7:1 and 2.2:1, respectively. Insertion allelotype, genotypes with ins/ins, as well as ins allele carrier (ins/ins+ ins/del) were significantly greater in gastric cancer patients than in controls, especially in patients >65 years old, but not in younger patients. The polymorphism did not correlate with clinicopathologic factors and patient survival. NFKB1 could be a susceptible gene for gastric cancer and its functional polymorphism in promoter is associated with the risk of gastric cancer, particularly in aged patients.
    Surgery 04/2009; 145(3):280-5. DOI:10.1016/j.surg.2008.11.001 · 3.38 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: KRAB-associated protein 1 (KAP1) is a universal corepressor for Kruppel-associated box zinc finger proteins. Here we demonstrate the biological function and clinical significance of KAP1 expression in gastric cancer. Knockdown of the KAP1 gene by siRNA transfection was performed to evaluate KAP1 function in gastric cancer cells. Real-time polymerase chain reaction was performed in 91 samples obtained from gastric cancer patients. The proliferation rate was impaired and resistance to anoikis was decreased after knockdown of KAP1 in the gastric cancer cell lines AZ521 and KATO III. Expression of the KAP1 gene was significantly higher in cancerous tissues than in noncancerous tissues (P < .05). Patients with high KAP1 expression showed a higher incidence of peritoneal carcinomatosis (P < .05) and significantly poorer overall survival compared to patients with low KAP1 expression (5-year overall survival rates, 35.4% and 50.5%, respectively; P < .05). Multivariate analysis revealed that high KAP1 expression was an independent prognostic factor (risk ratio, 1.44; 95% confidence interval, 1.03-1.99; P < .05). Intriguingly, high KAP1 expression was also an independent factor for peritoneal carcinomatosis (odds ratio, 4.53; 95% confidence interval, 1.27-18.5; P < .05). KAP1 provides a survival advantage to gastric cancer cells and is an independent factor for peritoneal dissemination in patients with gastric cancer. These results suggest that KAP1 plays an important role in progression to peritoneal carcinomatosis in gastric cancer patients.
    Annals of Surgical Oncology 11/2009; 17(3):821-8. DOI:10.1245/s10434-009-0795-8 · 3.93 Impact Factor
Show more